Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Calmodulin-dependent Signaling01:16

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mn(III)-Catalyzed Synthesis of Selenophosphates and Tellurophosphates.

Molecules (Basel, Switzerland)·2026
Same author

Divergent activation of the RXFP1 relaxin receptor by protein and small molecule agonists.

bioRxiv : the preprint server for biology·2026
Same author

Transformer-based framework uncovers state-dependent modular organization and conformational landscapes of the β-arrestin 1 C-terminal tail.

bioRxiv : the preprint server for biology·2026
Same author

Sympathetic immunomodulation suppresses liver metastasis by maintaining the balance between norepinephrine concentration and the α2a/β2-AR ratio.

Cellular & molecular immunology·2026
Same author

Targeting Hsc70-mediated mitochondrial-lipid droplet crosstalk via Ginsenoside Rb2 promotes post-infarction cardiomyocyte regeneration.

Pharmacological research·2026
Same author

Lipoblastoma of the head and neck in children: a single-institution study.

BMC pediatrics·2026
Same journal

Family of magnetic field-boosted superconductors in rhombohedral graphene.

Nature·2026
Same journal

What's the human cost of US research turmoil? A new film finds out.

Nature·2026
Same journal

Daily briefing: Ovaries start a second job after menopause.

Nature·2026
Same journal

Audio long read: Is the peptide craze backed by science? The promise behind the hype.

Nature·2026
Same journal

Scientists fight back against far-right plans to restrict academic freedom in Germany.

Nature·2026
Same journal

How AI can crack open the 'hidden curriculum' for neurodivergent students.

Nature·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Small-molecule modulation of β-arrestins.

Alem W Kahsai1, Natalia Pakharukova2, Henry Y Kwon2,3

  • 1Department of Medicine, Duke University Medical Center, Durham, NC, USA. alem@receptor-biol.duke.edu.

Nature
|June 24, 2026
PubMed
Summary
This summary is machine-generated.

Researchers developed small-molecule inhibitors targeting beta-arrestins (β-arrestins), crucial regulators of G-protein-coupled receptor (GPCR) signaling. These compounds selectively block beta-arrestin interactions with GPCRs, offering new therapeutic strategies.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Single Molecule Methods for Monitoring Changes in Bilayer Elastic Properties
12:20

Single Molecule Methods for Monitoring Changes in Bilayer Elastic Properties

Published on: November 3, 2008

Related Experiment Videos

Last Updated: Jun 26, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Single Molecule Methods for Monitoring Changes in Bilayer Elastic Properties
12:20

Single Molecule Methods for Monitoring Changes in Bilayer Elastic Properties

Published on: November 3, 2008

Area of Science:

  • Pharmacology and Molecular Biology
  • G-protein-coupled receptor (GPCR) signaling pathways
  • Protein-protein interactions

Background:

  • Beta-arrestins (β-arrestins) are key regulators of GPCR signaling, involved in diverse physiological responses.
  • Existing GPCR drug development targets orthosteric/allosteric sites, G proteins, and kinases, but lacks direct β-arrestin modulators.
  • A need exists for chemical tools to specifically modulate β-arrestin activity.

Purpose of the Study:

  • To identify and characterize small-molecule inhibitors that selectively target β-arrestins.
  • To elucidate the mechanism of action for these β-arrestin modulators.
  • To explore the therapeutic potential of targeting β-arrestin-mediated GPCR signaling.

Main Methods:

  • Integrated pharmacological, biochemical, biophysical, and structural analyses.
  • Cryo-electron microscopy (Cryo-EM) and molecular dynamics (MD) simulations.
  • Structure-guided mutagenesis to understand inhibitor-protein interactions.

Main Results:

  • Identification of small-molecule inhibitors that selectively disrupt β-arrestin engagement with activated GPCRs.
  • Demonstration that inhibitors impair GPCR desensitization, internalization, and β-arrestin-dependent functions while preserving G protein coupling.
  • Structural analysis revealed a specific allosteric binding site on β-arrestin1 (Cmpd-5) that stabilizes an inactive conformation, preventing receptor interaction.

Conclusions:

  • Establishment of a mechanistic framework for β-arrestin modulation using small molecules.
  • Discovery of a novel allosteric site on β-arrestins suitable for structure-based drug design.
  • Opening new therapeutic avenues for pathway-specific GPCR agents targeting transducers.